137 related articles for article (PubMed ID: 34714424)
1. Dose-reduced [
Valind K; Jögi J; Minarik D; Brolin G; Trägårdh E
EJNMMI Phys; 2021 Oct; 8(1):70. PubMed ID: 34714424
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. [
Valind K; Minarik D; Garpered S; Persson E; Jögi J; Trägårdh E
Eur J Hybrid Imaging; 2023 Nov; 7(1):25. PubMed ID: 37996712
[TBL] [Abstract][Full Text] [Related]
4. Renal Cortical
Sarikaya I; Alqallaf A; Sarikaya A
J Nucl Med Technol; 2021 Mar; 49(1):30-33. PubMed ID: 32887764
[No Abstract] [Full Text] [Related]
5. [
Valind K; Jögi J; Minarik D; Trägårdh E
Clin Physiol Funct Imaging; 2023 Mar; 43(2):128-135. PubMed ID: 36385577
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Radionuclide Renal Cortical Imaging in Pyelonephritis.
Sarikaya I; Sarikaya A
J Nucl Med Technol; 2019 Dec; 47(4):309-312. PubMed ID: 31182659
[TBL] [Abstract][Full Text] [Related]
7. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and radiation dosimetry of [
Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
[TBL] [Abstract][Full Text] [Related]
10. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
11. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
12. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Afshar-Oromieh A; Hetzheim H; Kübler W; Kratochwil C; Giesel FL; Hope TA; Eder M; Eisenhut M; Kopka K; Haberkorn U
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
[TBL] [Abstract][Full Text] [Related]
14. Optimization of PET protocol and interrater reliability of
Piron S; De Man K; Schelfhout V; Van Laeken N; Kersemans K; Achten E; De Vos F; Ost P
EJNMMI Res; 2020 Feb; 10(1):14. PubMed ID: 32095919
[TBL] [Abstract][Full Text] [Related]
15. Optimal time-point for
Beheshti M; Paymani Z; Brilhante J; Geinitz H; Gehring D; Leopoldseder T; Wouters L; Pirich C; Loidl W; Langsteger W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1188-1196. PubMed ID: 29476228
[TBL] [Abstract][Full Text] [Related]
16. Radiation Dosimetry and Biodistribution of
Piron S; De Man K; Van Laeken N; D'Asseler Y; Bacher K; Kersemans K; Ost P; Decaestecker K; Deseyne P; Fonteyne V; Lumen N; Achten E; Brans B; De Vos F
J Nucl Med; 2019 Dec; 60(12):1736-1742. PubMed ID: 31028165
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
19. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
